Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
1. Does transplant medicine have a new blood test that is better than creatinine?
— Nephrology Jrnl Club (@NephJC) July 1, 2022
Aye aye ADMIRAL 🫡
Join us as we recap last week's #NephJC chat on this edition of #TenTweetNephJC brought to you by @jamiekwillows and @michaelturk6 pic.twitter.com/gAS70VKG8i